8-K: STAAR Surgical Achieves Record Sales, Raises Full-Year Outlook

STAAR Surgical reported record quarterly net sales of $99.0 million, or $100.4 million in constant currency, and raised its fiscal year 2024 net sales and adjusted EBITDA outlook.

Summary

• STAAR Surgical announced record net sales for the second quarter of 2024, reaching $99.0 million, a 7% increase compared to the same period last year.
• In constant currency, net sales were $100.4 million, reflecting a 9% increase.
• ICL sales grew by 7% to $99.4 million, with unit growth of 3%.
• The company's gross margin improved to 79.2%, up from 76.6% year-over-year.
• Net income for the quarter was $7.4 million, or $0.15 per share, compared to $6.1 million, or $0.12 per share, in the prior year.
• Adjusted EBITDA reached $22.5 million, or $0.45 per share, compared to $18.3 million, or $0.37 per share, in the prior year.
• STAAR Surgical has increased its full-year 2024 net sales outlook to a range of $340 million to $345 million, and adjusted EBITDA to approximately $42 million.
• The company's cash, cash equivalents, and investments available for sale totaled $235.5 million as of June 28, 2024.

Sentiment

Score: 9

Explanation: The document conveys a very positive sentiment due to record sales, improved profitability, raised guidance, and strong market growth. The company's strategic initiatives and market position are also highlighted positively.

Positives

• The company achieved record net sales for the second quarter of 2024.
• Gross margin improved significantly year-over-year.
• Net income and adjusted EBITDA both increased compared to the prior year.
• The company raised its full-year outlook for both net sales and adjusted EBITDA.
• U.S. sales showed strong growth, increasing 25% year-over-year.
• The company is seeing strong growth in the Middle East and European distribution operations.
• The company is moving down the diopter curve, expanding its market opportunity.
• The company has a strong cash position with $235.5 million in cash, cash equivalents, and investments.

Negatives

• General and administrative expenses increased due to higher compensation-related expenses, facilities costs, and outside services.
• Research and development expenses increased due to higher compensation-related expenses.
• The company experienced a loss on foreign currency transactions.
• Selling and marketing expenses decreased due to lower marketing, promotion and advertising activities.

Risks

• The company's performance is subject to global economic conditions.
• Regulatory agencies have the discretion to approve or reject products.
• International conflicts and trade disputes could impact the business.
• The company is substantially dependent on demand from Asia.
• The willingness of surgeons and patients to adopt new products and procedures is a risk.

Future Outlook

The company raised its fiscal year 2024 net sales outlook to a range of $340 million to $345 million and adjusted EBITDA to approximately $42 million. The outlook includes EVO ICL sales growth in the Americas of 15% including 25% in the U.S., EMEA sales growth of 6%, and APAC growth of 7%, including approximately 10% in China.

Management Comments

• Tom Frinzi, President and CEO, stated that the company reported record net sales for the second quarter of 2024, including milestone sales over $100 million on a constant currency basis.
• Mr. Frinzi noted that the company is committed to enhancing surgeon confidence and practice implementation, growing the category and seizing market share throughout the business cycle.
• Mr. Frinzi also mentioned that the company's commercial momentum is accelerating due to execution against their strategic priorities.
• Mr. Frinzi stated that the company is moving down the diopter curve and is beginning to realize their near-term goal of becoming the choice for surgeons and their patients -6D of myopia and above.

Industry Context

The announcement indicates that STAAR Surgical is gaining market share in the refractive surgery industry, particularly with its EVO ICL technology. The company's growth is occurring despite a generally flat to down refractive procedure market, suggesting a competitive advantage.

Comparison to Industry Standards

• STAAR Surgical's 7% global ICL sales growth and 3% unit growth in Q2 2024 compares favorably to the generally flat to down refractive procedure market globally.
• The company's 25% year-over-year sales growth in the U.S. is a strong indicator of market penetration and adoption compared to competitors in the region.
• STAAR's gross margin of 79.2% is high compared to many medical device companies, reflecting the premium nature of their product and efficient operations.
• The company's focus on moving down the diopter curve is a strategic move to expand its market reach, potentially competing with laser vision correction procedures.
• The company's 20%+ refractive market share in Japan, China and South Korea and 18%+ share in Spain indicates a strong global presence compared to other players in the market.

Stakeholder Impact

• Shareholders will benefit from the increased sales, profitability, and raised outlook.
• Surgeon customers will benefit from the enhanced EVO ICL technology and its impact on their practice economics.
• Patients will benefit from the visual freedom provided by the EVO ICL technology.

Next Steps

• The company will continue to focus on enhancing surgeon confidence and practice implementation.
• The company will continue to grow the category and seize market share.
• The company will continue to move down the diopter curve to expand its market opportunity.
• The company will host an earnings webcast to discuss its financial results and operational progress.

Key Dates

Keywords

ICL, Implantable Collamer Lens, EVO ICL, Refractive Surgery, Ophthalmology, Net Sales, Adjusted EBITDA, Gross Margin, Myopia, Astigmatism, Presbyopia